

Thomas Dörner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5496294/publications.pdf>

Version: 2024-02-01

246
papers

25,276
citations

8755

75
h-index

7950

149
g-index

279
all docs

279
docs citations

279
times ranked

24966
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance” by Bossuyt et al. Annals of the Rheumatic Diseases, 2023, 82, e194-e194.	0.9	6
2	Response to: “2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus” by Aringer et al. by Cui et al. Annals of the Rheumatic Diseases, 2022, 81, e166-e166.	0.9	47
3	Response to: “Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?” by Teng et al. Annals of the Rheumatic Diseases, 2022, 81, e23-e23.	0.9	3
4	Altered increase in STAT1 expression and phosphorylation in severe COVID-19. European Journal of Immunology, 2022, 52, 138-148.	2.9	33
5	Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus. Rheumatology, 2022, 61, 3396-3400.	1.9	5
6	Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet, The, 2022, 399, 161-171.	13.7	72
7	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. Computational and Structural Biotechnology Journal, 2022, 20, 471-484.	4.1	7
8	B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. Arthritis and Rheumatology, 2022, 74, 934-947.	5.6	55
9	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. JCI Insight, 2022, 7, .	5.0	62
10	B- and Plasma Cell Subsets in Autoimmune Diseases: Translational Perspectives. Journal of Investigative Dermatology, 2022, 142, 811-822.	0.7	5
11	Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. New England Journal of Medicine, 2022, 386, 1034-1045.	27.0	48
12	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Rheumatology and Therapy, 2022, 9, 781-802.	2.3	9
13	Resident memory CD4 ⁺ T lymphocytes mobilize from bone marrow to contribute to a systemic secondary immune reaction. European Journal of Immunology, 2022, 52, 737-752.	2.9	6
14	CD39 and CD326 Are Bona Fide Markers of Murine and Human Plasma Cells and Identify a Bone Marrow Specific Plasma Cell Subpopulation in Lupus. Frontiers in Immunology, 2022, 13, 873217.	4.8	9
15	B cells in systemic lupus erythematosus. Current Opinion in Rheumatology, 2022, 34, 125-132.	4.3	17
16	B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients. Frontiers in Immunology, 2022, 13, 822885.	4.8	7
17	Current and future treatment in primary Sjögren's syndrome—A still challenging development. Joint Bone Spine, 2022, 89, 105406.	1.6	8
18	Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. Journal of Clinical Immunology, 2022, 42, 1111-1129.	3.8	17

#	ARTICLE	IF	CITATIONS
19	Plasmablast-like Phenotype Among Antigen-Experienced CXCR5 ⁺ CD19 ^{low} B Cells in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2022, 74, 1556-1568.	5.6	10
20	Physician Global Assessment International Standardisation CONsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	3.9	17
21	Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Research and Therapy, 2022, 24, 112.	3.5	19
22	Biological impact of iberdomide in patients with active systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2022, 81, 1136-1142.	0.9	13
23	Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2022, 81, 1267-1272.	0.9	18
24	Advances in SLE classification criteria. Journal of Autoimmunity, 2022, 132, 102845.	6.5	11
25	Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2022, 81, 1556-1563.	0.9	24
26	Response to: "New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion" by Sacre <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e191-e191.	0.9	3
27	Response to: "European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view" by Infantino <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e189-e189.	0.9	28
28	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501.	3.4	60
29	B cells in SLE. , 2021, , 131-138.		1
30	Treatment of Sjögren's syndrome: current therapy and future directions. Rheumatology, 2021, 60, 2066-2074.	1.9	55
31	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.9	158
32	Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nature Reviews Rheumatology, 2021, 17, 98-108.	8.0	143
33	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.9	37
34	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. Drugs and Aging, 2021, 38, 265-284.	2.7	4
35	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. Lupus Science and Medicine, 2021, 8, e000433.	2.7	7
36	27...Translational insights into the pathogenesis transforming SLE treatment. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
37	Deep Phenotyping of CD11c+ B Cells in Systemic Autoimmunity and Controls. <i>Frontiers in Immunology</i> , 2021, 12, 635615.	4.8	39
38	SARS-CoV-2 in severe COVID-19 induces a TGF- β -dominated chronic immune response that does not target itself. <i>Nature Communications</i> , 2021, 12, 1961.	12.8	145
39	BTLA Expression and Function Are Impaired on SLE B Cells. <i>Frontiers in Immunology</i> , 2021, 12, 667991.	4.8	12
40	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5397-5407.	1.9	48
41	POS0692: ANAALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 593-594.	0.9	0
42	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637.	3.8	12
43	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021, 6, eabj1031.	11.9	223
44	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. <i>Frontiers in Immunology</i> , 2021, 12, 690698.	4.8	52
45	Viscoelastic testing reveals normalization of the coagulation profile 12 weeks after severe COVID-19. <i>Scientific Reports</i> , 2021, 11, 13325.	3.3	5
46	Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2021, 33, 592-597.	4.3	9
47	Vaccine-Induced Thrombocytopenia with Severe Headache. <i>New England Journal of Medicine</i> , 2021, 385, 2103-2105.	27.0	79
48	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3027-3033.	6.1	82
49	Response to: Role of ANA testing in the classification of patients with systemic lupus erythematosus by Pisetsky et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e125-e125.	0.9	1
50	Effect of attribution on external validation of the EULAR/ACR SLE classification criteria. , 2021, , .		0
51	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
52	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). <i>European Journal of Immunology</i> , 2021, 51, 2708-3145.	2.9	198
53	Clinical trial and real-world data support switching from a bio-originator to its biosimilar. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e44-e44.	0.9	7
54	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 1820-1826.	3.4	28

#	ARTICLE	IF	CITATIONS
55	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.9	307
56	<sc>EZH2 Inhibition in B Cell Subsets: Comment on the Article by Rohraff et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 371-373.	5.6	2
57	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 695-696.	5.6	1
58	Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1389-1392.	0.9	7
59	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020, 7, e000424.	2.7	35
60	Therapeutic Cytokine Inhibition Modulates Activation and Homing Receptors of Peripheral Memory B Cell Subsets in Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2020, 11, 572475.	4.8	13
61	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	3.8	36
62	Role for antimalarials in the management of COVID-19. <i>Current Opinion in Rheumatology</i> , 2020, 32, 449-457.	4.3	7
63	Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus. <i>RMD Open</i> , 2020, 6, e001258.	3.8	10
64	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
65	09â€¦Novel intracellular pathways. , 2020, , .		0
66	04â€¦Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus. , 2020, , .		0
67	08â€¦Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
68	Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. <i>Critical Care</i> , 2020, 24, 676.	5.8	78
69	Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility. <i>Rheumatology</i> , 2020, 59, 3435-3442.	1.9	23
70	Human CD27+ memory B cells colonize a superficial follicular zone in the palatine tonsils with similarities to the spleen. A multicolor immunofluorescence study of lymphoid tissue. <i>PLoS ONE</i> , 2020, 15, e0229778.	2.5	14
71	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 155-166.	8.0	952
72	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 860-861.	5.6	0

#	ARTICLE	IF	CITATIONS
73	Reply. Arthritis and Rheumatology, 2020, 72, 1404-1404.	5.6	0
74	Human IgA-Expressing Bone Marrow Plasma Cells Characteristically Upregulate Programmed Cell Death Protein-1 Upon B Cell Receptor Stimulation. Frontiers in Immunology, 2020, 11, 628923.	4.8	7
75	Ianalumab (VAY736) in primary Sjögren's syndrome: assessing disease activity using multi-modal ultrasound. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 228-236.	0.8	3
76	How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. Arthritis and Rheumatology, 2019, 71, 91-98.	5.6	93
77	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.9	759
78	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	5.6	1,098
79	Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases. Frontiers in Immunology, 2019, 10, 2136.	4.8	41
80	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. RMD Open, 2019, 5, e001064.	3.8	53
81	Pathogenic memory plasma cells in autoimmunity. Current Opinion in Immunology, 2019, 61, 86-91.	5.5	26
82	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	2.9	766
83	Difference between SLE classification and diagnosis and importance of attribution. Response to: "Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?" by Chi et al. Annals of the Rheumatic Diseases, 2019, , annrheumdis-2019-216338.	0.9	4
84	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 634-640.	0.9	51
85	Novel paradigms in systemic lupus erythematosus. Lancet, The, 2019, 393, 2344-2358.	13.7	363
86	EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases, 2019, 78, 1296-1304.	0.9	664
87	Treatment of primary Sjögren's syndrome with Ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Annals of the Rheumatic Diseases, 2019, 78, 641-647.	0.9	113
88	Enhanced Programmed Death 1 and Diminished Programmed Death Ligand 1 Upregulation Capacity of Post-Activated Lupus B Cells. Arthritis and Rheumatology, 2019, 71, 1539-1544.	5.6	25
89	B cell subset distribution in human bone marrow is stable and similar in left and right femur: An instructive case. PLoS ONE, 2019, 14, e0212525.	2.5	2
90	Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis. Frontiers in Immunology, 2019, 10, 29.	4.8	10

#	ARTICLE	IF	CITATIONS
91	Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations. <i>Current Opinion in Rheumatology</i> , 2019, 31, 175-184.	4.3	20
92	Response to: "Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus" by Wang et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrheumdis-2019-216807.	0.9	0
93	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. <i>Lupus Science and Medicine</i> , 2019, 6, e000342.	2.7	15
94	Response to: "New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS" by Assan et al. <i>Annals of the Rheumatic Diseases</i> , 2019, , annrheumdis-2019-216250.	0.9	1
95	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	2.0	45
96	Reply. <i>Arthritis Care and Research</i> , 2019, 71, 696-697.	3.4	2
97	Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 937-945.	0.8	1
98	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 763-773.	5.6	49
99	Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 1488-1494.	3.4	48
100	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 741-758.	6.1	39
101	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018, 70, 428-438.	3.4	129
102	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018, 70, 571-581.	3.4	91
103	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 165-174.	0.9	173
104	Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis. <i>European Journal of Immunology</i> , 2018, 48, 194-203.	2.9	10
105	Motor and cognitive fatigue in SLE is associated with mood and health-related quality of life (HRQoL) in patients with SLE: results from the Patient Reported Outcomes in Lupus (PRO-Lupus) study. <i>Rheumatology</i> , 2018, 57, .	1.9	3
106	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	3.8	38
107	LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells. <i>Immunity</i> , 2018, 49, 120-133.e9.	14.3	190
108	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2018, 392, 222-231.	13.7	396

#	ARTICLE	IF	CITATIONS
109	Simultaneous Presence of Non- and Highly Mutated Keyhole Limpet Hemocyanin (KLH)-Specific Plasmablasts Early after Primary KLH Immunization Suggests Cross-Reactive Memory B Cell Activation. <i>Journal of Immunology</i> , 2018, 200, 3981-3992.	0.8	18
110	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
111	High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1476-1480.	0.9	43
112	Plasmablasts With a Mucosal Phenotype Contribute to Plasmacytosis in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 2018-2028.	5.6	28
113	Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. <i>Current Rheumatology Reports</i> , 2017, 19, 37.	4.7	79
114	Guidelines for the use of flow cytometry and cell sorting in immunological studies. <i>European Journal of Immunology</i> , 2017, 47, 1584-1797.	2.9	505
115	Drivers of the immunopathogenesis in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 321-333.	3.3	37
116	Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. <i>Rheumatology</i> , 2017, 56, 1618-1626.	1.9	49
117	Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1837-1844.	0.9	97
118	Considering biosimilar policy. <i>Considerations in Medicine</i> , 2017, 1, 19-24.	0.0	0
119	7 Neonatale Lupussyndrome. , 2017, , .		0
120	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.9	160
121	SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome. <i>RMD Open</i> , 2016, 2, e000292.	3.8	42
122	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	2.7	51
123	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1945-1950.	0.9	57
124	Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor. <i>Journal of Cell Communication and Signaling</i> , 2016, 10, 143-151.	3.4	14
125	Beyond pan-B-cell-directed therapy – new avenues and insights into the pathogenesis of SLE. <i>Nature Reviews Rheumatology</i> , 2016, 12, 645-657.	8.0	69
126	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225

#	ARTICLE	IF	CITATIONS
127	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 137-156.	3.0	118
128	A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. <i>Blood</i> , 2015, 125, 1739-1748.	1.4	170
129	Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 206.	3.5	10
130	Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B-cell Receptor Signaling and Promotes Survival of Human Lupus B-cells. <i>Arthritis and Rheumatology</i> , 2015, 68, n/a-n/a.	5.6	40
131	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	3.8	229
132	Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. <i>RMD Open</i> , 2015, 1, e000037.	3.8	17
133	The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2015, 14, 1079-1086.	5.8	59
134	Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , 2015, 54, 2230-2238.	1.9	220
135	CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 61.	3.5	56
136	Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF- α , but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 185.	3.5	46
137	Biosimilars in rheumatology: current perspectives and lessons learnt. <i>Nature Reviews Rheumatology</i> , 2015, 11, 713-724.	8.0	96
138	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193
139	Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 347-53.	0.8	9
140	Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation. <i>Arthritis Research and Therapy</i> , 2014, 16, 477.	3.5	47
141	Increased Frequency of a Unique Spleen Tyrosine Kinase Bright Memory B Cell Population in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2014, 66, 3424-3435.	5.6	58
142	B cells. <i>Current Opinion in Rheumatology</i> , 2014, 26, 228-236.	4.3	40
143	Outcome measures for primary Sjögren's syndrome: A comprehensive review. <i>Journal of Autoimmunity</i> , 2014, 51, 51-56.	6.5	77
144	IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. <i>Nature</i> , 2014, 507, 366-370.	27.8	882

#	ARTICLE	IF	CITATIONS
145	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
146	Emerging cell and cytokine targets in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 77-88.	8.0	260
147	Tissue Distribution and Dependence of Responsiveness of Human Antigen-Specific Memory B Cells. <i>Journal of Immunology</i> , 2014, 192, 3091-3100.	0.8	83
148	Immunopathogenic mechanisms of systemic autoimmune disease. <i>Lancet, The</i> , 2013, 382, 819-831.	13.7	446
149	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 322-328.	0.9	166
150	CD22 ligation inhibits downstream B cell receptor signaling and Ca ²⁺ flux upon activation. <i>Arthritis and Rheumatism</i> , 2013, 65, 770-779.	6.7	70
151	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.9	114
152	Antiphospholipid antibody profiling – Time for a new technical approach?. <i>Autoimmunity Reviews</i> , 2012, 11, 821-826.	5.8	39
153	CD22 and Autoimmune Disease. <i>International Reviews of Immunology</i> , 2012, 31, 363-378.	3.3	43
154	Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. <i>Arthritis Research and Therapy</i> , 2012, 14, S1.	3.5	78
155	Deciphering the role of NETs and networks in SLE. <i>Nature Reviews Rheumatology</i> , 2012, 8, 68-70.	8.0	25
156	Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 738-746.	8.0	48
157	Joint European League Against Rheumatism and European Renal Association – European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.9	868
158	Mechanisms of B cell autoimmunity in SLE. <i>Arthritis Research and Therapy</i> , 2011, 13, 243.	3.5	225
159	EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 968-972.	0.9	383
160	Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. <i>Arthritis Research and Therapy</i> , 2011, 13, R118.	3.5	34
161	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011, 13, R75.	3.5	170
162	Abnormalities of B cell subsets in patients with systemic lupus erythematosus. <i>Journal of Immunological Methods</i> , 2011, 363, 187-197.	1.4	111

#	ARTICLE	IF	CITATIONS
163	In vivo effects of the anti-IL-6 receptor inhibitor tocilizumab on the B cell compartment. <i>Arthritis and Rheumatism</i> , 2011, 63, 1255-1264.	6.7	87
164	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.9	394
165	Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in pre-switch memory B cells and modulation of mutational targeting in memory B cells. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1507-1510.	0.9	38
166	Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. <i>Blood</i> , 2010, 116, 5181-5190.	1.4	107
167	Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers. , 2010, 125, 464-475.		93
168	What do we know about memory B cells in primary Sjögren's syndrome?. <i>Autoimmunity Reviews</i> , 2010, 9, 600-603.	5.8	28
169	Memory B and memory plasma cells. <i>Immunological Reviews</i> , 2010, 237, 117-139.	6.0	242
170	Secondary Immunization Generates Clonally Related Antigen-Specific Plasma Cells and Memory B Cells. <i>Journal of Immunology</i> , 2010, 185, 3103-3110.	0.8	78
171	Current aspects of anti-CD20 therapy in rheumatoid arthritis. <i>Current Opinion in Pharmacology</i> , 2010, 10, 316-321.	3.5	28
172	Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 12, R204.	3.5	86
173	The Role of B Cells in Rheumatoid Arthritis. , 2009, , 97-106.		1
174	Expression of Proteasomal Immunoglobulin G1 is Dysregulated in Inflammatory Infiltrates of Minor Salivary Glands in Sjögren's Syndrome. <i>Journal of Rheumatology</i> , 2009, 36, 2694-2703.	2.0	22
175	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009, 9, 82-89.	5.8	62
176	Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. <i>Clinical Immunology</i> , 2009, 130, 199-212.	3.2	56
177	Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. <i>Arthritis and Rheumatism</i> , 2009, 60, 2284-2293.	6.7	37
178	Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2009, 11, 255.	3.5	10
179	B cells in autoimmunity. <i>Arthritis Research and Therapy</i> , 2009, 11, 247.	3.5	130
180	B-cell-directed therapies for autoimmune disease. <i>Nature Reviews Rheumatology</i> , 2009, 5, 433-441.	8.0	152

#	ARTICLE	IF	CITATIONS
181	Anticytokine therapy impacting on B cells in autoimmune diseases. <i>Current Opinion in Rheumatology</i> , 2009, 21, 205-210.	4.3	30
182	Blood-borne human plasma cells in steady state are derived from mucosal immune responses. <i>Blood</i> , 2009, 113, 2461-2469.	1.4	230
183	Plasma cell differentiation and survival. <i>Current Opinion in Immunology</i> , 2008, 20, 162-169.	5.5	178
184	Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment. <i>Arthritis and Rheumatism</i> , 2008, 58, 1566-1575.	6.7	167
185	Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. <i>Arthritis and Rheumatism</i> , 2008, 58, 1762-1773.	6.7	263
186	New approaches of B-cell-directed therapy: beyond rituximab. <i>Current Opinion in Rheumatology</i> , 2008, 20, 263-268.	4.3	82
187	B-cell targeting: a novel approach to immune intervention today and tomorrow. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1287-1299.	3.1	32
188	Antibodies and B Cell Memory in Viral Immunity. <i>Immunity</i> , 2007, 27, 384-392.	14.3	247
189	B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. <i>Arthritis Research and Therapy</i> , 2007, 9, 218.	3.5	124
190	High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2007, 136, 309-314.	2.5	105
191	Phenotypic Analysis of B-Cells and Plasma Cells. <i>Methods in Molecular Medicine</i> , 2007, 136, 3-18.	0.8	9
192	Targeting CD22 as a strategy for treating systemic autoimmune diseases. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 953-9.	2.0	28
193	Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006, 8, R74.	3.5	267
194	Contribution of B Cells to Autoimmune Pathogenesis. , 2006, , 461-501.		0
195	Adaptation of humoral memory. <i>Immunological Reviews</i> , 2006, 211, 295-302.	6.0	73
196	Competence and competition: the challenge of becoming a long-lived plasma cell. <i>Nature Reviews Immunology</i> , 2006, 6, 741-750.	22.7	882
197	Immunopathologic role of B lymphocytes in rheumatoid arthritis: Rationale of B cell-directed therapy. <i>Autoimmunity Reviews</i> , 2006, 5, 437-442.	5.8	63
198	Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 2377-2386.	6.7	282

#	ARTICLE	IF	CITATIONS
199	Implant-related inflammatory arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 53-56.	3.2	25
200	Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. <i>Journal of rheumatology Supplement, The</i> , 2006, 77, 3-11.	2.2	58
201	Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. <i>Current Opinion in Rheumatology</i> , 2005, 17, 558-565.	4.3	98
202	Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2005, 52, 2109-2119.	6.7	70
203	Molecular basis of immunoglobulin variable region gene usage in systemic autoimmunity. <i>Clinical and Experimental Medicine</i> , 2005, 4, 159-169.	3.6	30
204	Antibodies against protein Z and fetal loss: current perspectives. <i>Clinical and Experimental Medicine</i> , 2005, 5, 50-54.	3.6	8
205	Cryopreserved Human B Cells as an Alternative Source for Single Cell mRNA Analysis. <i>Cell and Tissue Banking</i> , 2005, 6, 299-308.	1.1	7
206	Selecting B cells and plasma cells to memory. <i>Journal of Experimental Medicine</i> , 2005, 201, 497-499.	8.5	35
207	Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. <i>Blood</i> , 2005, 105, 1614-1621.	1.4	383
208	Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2005, 7, R1001.	3.5	110
209	Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. <i>Arthritis Research</i> , 2005, 7, R714.	2.0	46
210	Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2004, 50, 1897-1908.	6.7	99
211	Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 3211-3220.	6.7	179
212	Autoantibodies in normals--the value of predicting rheumatoid arthritis. <i>Arthritis Research</i> , 2004, 6, 282.	2.0	11
213	Rheumatoid factor revisited. <i>Current Opinion in Rheumatology</i> , 2004, 16, 246-253.	4.3	193
214	Correlation between circulating CD27 ^{high} plasma cells and disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 1332-1342.	6.7	319
215	Development of systemic lupus erythematosus in a patient with congenital heart block. <i>Arthritis and Rheumatism</i> , 2003, 48, 2697-2698.	6.7	5
216	Aberrant Activation of B Cells in Patients with Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2003, 987, 246-248.	3.8	54

#	ARTICLE	IF	CITATIONS
217	New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. <i>Current Opinion in Rheumatology</i> , 2003, 15, 563-570.	4.3	64
218	The role of B cells in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2003, 15, 246-252.	4.3	133
219	Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in VH4-34 expressing single leukemic B cells. <i>Blood</i> , 2002, 100, 3419-3422.	1.4	45
220	Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome. <i>Arthritis Research</i> , 2002, 4, 360.	2.0	40
221	Immunoglobulin repertoire analysis provides new insights into the immunopathogenesis of Sjögren's syndrome. <i>Autoimmunity Reviews</i> , 2002, 1, 119-124.	5.8	32
222	A serologic marker for fetal risk of congenital heart block. <i>Arthritis and Rheumatism</i> , 2002, 46, 1233-1241.	6.7	135
223	Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2002, 46, 2160-2171.	6.7	241
224	Perturbations in the impact of mutational activity on V λ genes in systemic lupus erythematosus. <i>Arthritis Research</i> , 2001, 3, 368.	2.0	14
225	Enhanced Mutational Activity and Disturbed Selection of Mutations in V κ Gene Rearrangements in a Patient with Systemic Lupus Erythematosus. <i>Autoimmunity</i> , 2001, 33, 61-76.	2.6	21
226	Immunoglobulin V λ light chain gene analysis in patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2001, 44, 626-637.	6.7	21
227	Immunoglobulin V λ light chain gene usage in patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2001, 44, 2620-2632.	6.7	22
228	Immunoglobulin variable-region gene usage in systemic autoimmune diseases. <i>Arthritis and Rheumatism</i> , 2001, 44, 2715-2727.	6.7	43
229	Smaller role for pol λ ?. <i>Nature Immunology</i> , 2001, 2, 982-983.	14.5	10
230	Significance of Autoantibodies in Neonatal Lupus Erythematosus. <i>International Archives of Allergy and Immunology</i> , 2000, 123, 58-66.	2.1	31
231	Editorial Overview: Antinuclear Antibody- and Extractable Nuclear Antigen-Related Diseases. <i>International Archives of Allergy and Immunology</i> , 2000, 123, 5-9.	2.1	18
232	Targeting and selection of mutations in human V λ rearrangements. <i>European Journal of Immunology</i> , 2000, 30, 1597-1605.	2.9	31
233	The influence of CD40 \leftrightarrow CD154 interactions on the expressed human VH repertoire: analysis of VH genes expressed by individual B cells of a patient with X-linked hyper-IgM syndrome. <i>International Immunology</i> , 2000, 12, 767-775.	4.0	25
234	Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2000, 165, 5970-5979.	0.8	564

#	ARTICLE	IF	CITATIONS
235	Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the β and γ type. <i>Arthritis and Rheumatism</i> , 1999, 42, 697-702.	6.7	60
236	Targeting and subsequent selection of somatic hypermutations in the human VH^{δ} repertoire. <i>European Journal of Immunology</i> , 1999, 29, 3122-3132.	2.9	27
237	Somatic hypermutation of VH^{δ} rearrangements: targeting of RGYW motifs on both DNA strands and preferential selection of mutated codons within RGYW motifs. <i>European Journal of Immunology</i> , 1999, 29, 4011-4021.	2.9	48
238	Enhanced Mutational Activity of VH^{δ} Gene Rearrangements in Systemic Lupus Erythematosus. <i>Clinical Immunology</i> , 1999, 92, 188-196.	3.2	40
239	Analysis of the targeting of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human V rearrangements. <i>Immunological Reviews</i> , 1998, 162, 161-171.	6.0	95
240	Comparable impact of mutational and selective influences in shaping the expressed repertoire of peripheral IgM ⁺ /CD5 ⁺ and IgM ⁺ /CD5 ⁺ B cells. <i>European Journal of Immunology</i> , 1998, 28, 657-668.	2.9	33
241	Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. <i>European Journal of Immunology</i> , 1998, 28, 3384-3396.	2.9	117
242	Similar characteristics of the CDR3 of VH 1-69/DP-10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells. <i>British Journal of Haematology</i> , 1998, 102, 516-521.	2.5	24
243	Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. <i>European Journal of Immunology</i> , 1998, 28, 3384-3396.	2.9	1
244	Significantly Increased Maternal and Fetal IgG autoantibody levels to 52kD Ro(SS-A) and La(SS-B) in Complete Congenital Heart Block. <i>Journal of Autoimmunity</i> , 1995, 8, 675-684.	6.5	46
245	Detection of Autoantibodies to Ro(SS-A), La(SS-B) and U1RNP in Different Congenital Heart Rhythm Disorders Using Immunoblot and Enzyme Immunoassay. <i>Journal of Autoimmunity</i> , 1994, 7, 93-106.	6.5	21
246	Mobilization of Tissue-Resident Memory CD4 ⁺ T Lymphocytes and Their Contribution to a Systemic Secondary Immune Reaction. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0